Lower paraoxonase 1 activity in Tunisian bipolar I patients

Annals of General Psychiatry

Volumn 9, Issue , 2010, Pages

  Ezzaher, Asma ^a   Mouhamed, Dhouha H ^a   Mechri, Anwar ^a   Araoud, Manel ^a   Neffati, Fadoua ^a   Douki, Wahiba ^a   Gaha, Lotfi ^a   Najjar, Mohamed F ^a  

^a UNIVERSITY OF MONASTIR   (Tunisia)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; ARYLDIALKYLPHOSPHATASE 1; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; ALCOHOL CONSUMPTION; ARTICLE; BIPOLAR I DISORDER; BODY MASS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; HUMAN; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MANIA; SMOKING; TRIACYLGLYCEROL BLOOD LEVEL; TUNISIA;

EID: 77958051860     PISSN: None     EISSN: 1744859X     Source Type: Journal    
DOI: 10.1186/1744-859X-9-36     Document Type: Article

References (18)

1. Andreazza AC, Kauer-Sant'Anna M, Frey BN, Bond DJ, Kapczinski F, Young Yatham LN. Oxidative stress markers in bipolar disorder: a meta-analysis. J Affect Disord 2008, 111:135-144. 10.1016/j.jad.2008.04.013, 18539338.
2. Sarkar PD, Shivaprakash TM, Madhusudhan B. Association between paraoxonase activity and lipid levels in patients with premature coronary artery disease. Clin Chim Acta 2006, 373:77-81. 10.1016/j.cca.2006.05.005, 16797516.
3. Wozniak J, Biederman J, Mick E, Waxmonsky J, Hantsoo L, Best C, Cluette-Brown JE, Laposata M. Omega-3 fatty acid monotherapy for pediatric bipolar disorder: a prospective open-label trial. Eur Neuropsychopharmacol 2007, 17:440-447. 10.1016/j.euroneuro.2006.11.006, 17258897.
4. Mackness MI, Arrol S, Abbott CA, Durrington PN. Protection of low-density lipoprotein against oxidative modification by high density lipoprotein associated paraoxonase. Atherosclerosis 1993, 104:129-135. 10.1016/0021-9150(93)90183-U, 8141836.
5. Witzum JL. The oxidation hypothesis of atherosclerosis. Lancet 1994, 344:793-795. 10.1016/S0140-6736(94)92346-9, 7916078.
6. Gan KN, Smolen A, Eckerson HW, La Du BN. Purification of human serum paraoxonase/arylesterase: evidence for one esterase catalyzing both activities. Drug Metab Dispos 1991, 19:100-106.
7. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders 2004, Washington DC, USA: American Psychiatric Association, 4, American Psychiatric Association.
8. World Health Organization Obesity: Preventing and Managing the Global Epidemic (publication WHO/NUT/NCD/98.1) 1997, Geneva, Switzerland: The World Health Organization, World Health Organization.
9. Garcia-Portilla MP, Saiz PA, Bascaran MT, Martinez S, Benabarre A, Sierra P, Torres P, Montes JM, Bousono M, Bobes J. Cardiovascular risk in patients with bipolar disorder. J Affect Disord 2009, 115:1-7. 10.1016/j.jad.2008.09.008, 19000640.
10. Matsumoto C, Ohmori O, Hori H, Shinkai T, Nakamura J. Analysis of association between the Gln 192 Arg polymorphism of the paraoxonase gene and schizophrenia in humans. Neurosci Lett 2002, 321:165-168. 10.1016/S0304-3940(02)00049-6, 11880198.
11. Chung KH, Tsai SY, Lee HC. Mood symptoms and serum lipids in acute phase of bipolar disorder in Taiwan. Psychiatry Clin Neurosci 2007, 61:428-433. 10.1111/j.1440-1819.2007.01689.x, 17610669.
12. Muldoon MF, Ryan CM, Matthews KA, Manuck SB. Serum cholesterol and intellectual performance. Psychosom Med 1997, 59:382-387.
13. Senti M, Toma's M, Anglada R, Elosua R, Marrugat J, Covas MI, Fito M. Interrelationship of smoking, paraoxonase activity, and leisure time physical activity: a population-based study. Eur J Int Med 2003, 14:178-184.
14. Nishio E, Watanabe Y. Cigarette smoke extract inhibits plasma paraoxonase activity by modification of the enzyme's free thiols. Biochem Biophys Res Com 1997, 236:289-293. 10.1006/bbrc.1997.6961, 9240427.
15. Sierksma A, vander Gaag MS, van Tol A, James RW, Hendriks FJ. Kinetics of HDL cholesterol and paraoxonase activity in moderate alcohol consumers. Alcohol Clin Exp Res 2002, 26:1430-1435.
16. Murray DP, Weiner M, Prabhakar M, Fiedorowicz JG. Mania and mortality: why the excess cardiovascular risk in bipolar disorder?. Curr Psychiatr Rep 2009, 11:475-480.
17. Angst F, Stassen HH, Clayton PJ, Angst J. Mortality of patients with mood disorders: follow-up over 34-38 years. J Affect Disord 2002, 68:167-181. 10.1016/S0165-0327(01)00377-9, 12063145.
18. Ani M, Moshtaghie AA, Akbarzadeh S. Changes in biochemical parameters related to lipid metabolism following lithium treatment in rat. Iran Biomed J 2005, 9:27-32.